Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background: The combinative regimens using oral nucleos(t)ide analogs (NA) plus either regular or on-demand low dose hepatitis B immunoglobulin (HBIG) have shown significant decrease in recurrence of post-liver transplantation (LT) hepatitis B, leading to considerable cost saving. Most of the protocols aimed to maintain hepatitis B surface antibody (HBsAb) levels above 100 IU/mL. Objective: To demonstrate that the maintenance threshold for HBsAb level could be lowered to 50 IU/mL for hepatitis B virus (HBV) prophylaxis during post-LT. Materials and Methods: The authors conducted a retrospective study of 45 patients that undergone LT for HBV-related diseases between 2003 and 2015. All patients had been followed-up and placed on a post-LT anti-HBV regimen of on-demand low-dose HBIG plus NAs. A fixed dose of 800 U HBIG was given as required to maintain HBsAb levels above 50 IU/mL. HBV recurrence was defined as persistent reappearance of HBsAg. Results: The mean follow-up was 57.8±38.3 months (range 6 months to 12 years), and no patient experienced HBV recurrence during that period. However, two patients experienced a few episodes of non-sustained HBsAg seropositivity without active disease, which indicated an actuarial risk of recurrence of 4.4%. The mean level of HBsAb in each stratified period was well maintained above 50 IU/mL. The estimated cost of HBIG was approximately 50% of the cost for the regular low-dose regimen. Conclusion: The present regimen yielded good result and significant cost reduction. The authors propose the maintenance HBsAb level could be reduced to 50 IU/mL without compromising the clinical outcome.

Type

Journal article

Journal

Journal of the Medical Association of Thailand

Publication Date

01/03/2019

Volume

102

Pages

312 - 319